Internal link ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets Dezembro 08, 2023 at 12:30 PM UTC
Internal link ProQR Announces Third Quarter 2023 Operating and Financial Results Novembro 07, 2023 at 12:00 PM UTC
Internal link ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing Novembro 06, 2023 at 12:00 PM UTC
Internal link ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference Setembro 28, 2023 at 12:00 PM UTC
Internal link ProQR Therapeutics Provides Update on Ophthalmic Assets Setembro 27, 2023 at 11:00 AM UTC
Internal link ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference Setembro 07, 2023 at 12:00 PM UTC
Internal link ProQR Announces Second Quarter 2023 Operating and Financial Results Agosto 03, 2023 at 11:00 AM UTC
Internal link ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets Agosto 01, 2023 at 11:00 AM UTC
Internal link ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit Julho 06, 2023 at 11:00 AM UTC
Internal link ProQR Announces First Quarter 2023 Operating and Financial Results Maio 16, 2023 at 11:00 AM UTC
Internal link ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023 Maio 09, 2023 at 12:00 PM UTC
Internal link ProQR Announces Upcoming Investor Conferences in April and May Abril 20, 2023 at 12:00 PM UTC
Internal link ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023 Abril 18, 2023 at 12:00 PM UTC
Internal link ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event Março 29, 2023 at 12:00 PM UTC
Internal link ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing Março 14, 2023 at 12:00 PM UTC
Internal link ProQR to Present at Upcoming Scientific and Industry Conferences Março 07, 2023 at 01:00 PM UTC
Internal link ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023 Fevereiro 28, 2023 at 01:00 PM UTC
Internal link ProQR Therapeutics Added to NASDAQ Biotechnology Index Dezembro 24, 2018 at 12:00 PM UTC
Internal link ProQR annonce la publication dans Nature Medicine des données du QR-110 pour l’amaurose congénitale de Leber 10 Dezembro 18, 2018 at 03:27 PM UTC
Internal link ProQR Announces Publication in Nature Medicine of QR-110 Data for Leber’s Congenital Amaurosis 10 Dezembro 17, 2018 at 04:52 PM UTC
Internal link ProQR Announces Strategic Changes to the Management Team and Key New Hires Dezembro 13, 2018 at 12:00 PM UTC
Internal link ProQR Receives € 4.7 million in Innovation Credit from Dutch Government for QR-110 for LCA10 Dezembro 10, 2018 at 12:00 PM UTC
Internal link ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients Dezembro 04, 2018 at 12:00 PM UTC
Internal link ProQR to Present at the Evercore ISI HealthConX Conference Novembro 20, 2018 at 12:00 PM UTC
Internal link ProQR Announces Financial Results for the Third Quarter of 2018 Novembro 07, 2018 at 12:00 PM UTC